Book a free 2-hour consultation with CTC advisory board.
Agenda - CTC advisory board
During your free consultation you have the possibility to discuss your preliminary study design with key experts at CTC and from our sister companies RegSmart, Toxicology Knowledge Team (TKT), Lablytica and Clinsmart regarding your upcoming clinical trial and to receive feedback to important aspects before the start of your trial. You will meet a handpicked team of scientific, medical, regulatory experts, pharmacokineticists, bioanalyticists, medical writers, biostatisticians and project managers. Together, we will discuss your opportunities, issues as well as advise you in how to most easily take your product into clinic or how to move forward into phase II. Before your scheduled visit, both parts will sign a CDA to be able to discuss the trial in a transparent way.
To bring home
- Input to your preliminary study design
- Important key elements to consider before the start of your trial
- Estimated cost (ballpark)
Send a request for a free 2-hour meeting
We translate science into treatment
Clinical Trial Consultants is a full-service CRO with focus on clinical conduct at our own research facilities, a first-in-human approved unit at Uppsala University Hospital (12 beds) and a phase I-II unit (24 beds) in Science Park, Uppsala. We have a long experience within clinical trials in early phase, from first-in-human to proof-of-concept. We offer a package deal including all key elements from advice of study design and protocol writing to the clinical conduct at own research units and/or multicenter trials, project management as well as biostatistics and report writing. We also have a well-established pharmacovigilance department with medical monitoring and reporting of adverse events as well as a patient recruitment team specialized in recruiting healthy volunteers and patient populations.
CTC started in 2011 and has since then successfully conducted over 350 industry sponsored clinical trials for startups, international pharmaceutical and MedTech companies, and CROs.